The U.S. FDA has granted orphan drug designation to MAIA Biotechnology, Inc., for its lead asset THIO, a cancer telomere-targeting agent for the treatment of glioblastoma. This is the third orphan drug designation granted to THIO, including designations for hepatocellular carcinoma (HCC) and small cell lung cancer (SCLC) in 2022. A Phase 2 trial of THIO, THIO-101, is evaluating the drug candidate in patients with advanced non-small cell lung cancer (NSCLC). THIO is the only direct telomere ta...